# Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/concurrent-cetuximab-and-nivolumab-as-a-second-line-or-beyond-treatment-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Christine H. Chung,Marcelo Bonomi,Conor Steuer,Jiannong Li,Priyanka Bhateja,Matthew Johnson,Jude Masannat,Feifei Song,Juan C. Hernandez‐Prera,Bruce M. Wenig,Helen Molina,Joaquim M. Farinhas,Caitlin McMullen,J. Trad Wadsworth,Krupal Patel,Julie A. Kish,Jameel Muzaffar,Kedar Kirtane,James W. Rocco,Michael J. Schell,Nabil F. Saba |
| Citations | 59 |
| DOI | 10.3390/cancers13051180 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.mdpi.com/2072-6694/13/5/1180/pdf?version=1615293479 |
| OpenAlex ID | https://openalex.org/W3133969996 |
| PMID | 33803335 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Kedar Kirtane](https://scholariq.org/researchers/kedar-kirtane/)

## Paper journal

- [Cancers](https://scholariq.org/journals/cancers/)

## Paper primary topic

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.